See other companies on Welcome to the Jungle
Dopavision
Digital myopia treatment
- 1-20 employees
- Healthcare
- B2C
- Virtual Reality
- MedTech
- Government District, Berlin, Germany
Jump to section
Company mission
Dopavision's mission is to pioneer the development of digital therapeutics in ophthalmology.
Our take
Myopia is on the rise, with around half the world’s population expected to be living with this sight condition by 2050. Also known as shortsightedness, it can begin to develop in childhood, and Dopavision is hoping to tackle it at this point through the use of pioneering digital therapeutics. Their MyopiaX solution involves children playing VR games for several minutes at a time whilst receiving dopamine-stimulating light treatment to help the eye grow correctly.
The rise of myopia is in part attributed to the use of personal devices for increasing lengths of time, and at an increasingly young age. So Dopavision’s solution, if it is effective, seems guaranteed to be in high demand over future years. Additionally, the dopamine stimulating solution could prove effective in the treatment or prevention of other eye diseases with similar causes.
Dopavision’s first digital myopia treatment is still going through clinical trials, so not much can be said regarding its market success. However, much may hang on it if it receives approval. Certainly the digital therapeutic is a novel idea, and with a substantial market and growing demand, it could prove a highly lucrative one.
Kirsty
Company Specialist at Welcome to the Jungle
Funding (2 rounds)
Jul 2021
$12.7m
SERIES A
Jun 2019
$1.4m
SEED
Total funding: $14.1m
Leadership
Dr. Hamed Bahmani
(Co-founder & Managing Director)Previously CTO, Data Scientist, and Head of Research at the Flying Health Incubator, before moving on to take various positions at the Max Planck Institute.
Stefan Zundel
(Co-founder & Managing Director)Previously an engagement manager at McKinsey, before moving on to found Cubitabo. Went on to work in venture development at Flying Health Incubator.